Risperidone Mylan

New Zealand - English - Medsafe (Medicines Safety Authority)

Active ingredient:
Risperidone 2 mg
Available from:
Viatris Limited
INN (International Name):
Risperidone 2 mg
Dosage:
2 mg
Pharmaceutical form:
Film coated tablet
Composition:
Active: Risperidone 2 mg Excipient: Colloidal silicon dioxide Lactose monohydrate Magnesium stearate Microcrystalline cellulose Opadry orange 03H53577 Sodium laurilsulfate Starch
Prescription type:
Prescription
Manufactured by:
Mylan Laboratories Limited
Therapeutic indications:
Indicated for the treatment of schizophrenia and other psychotic disorders. These include first episode pyschoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent. Risperidone also alleviates affective symptoms (such as depression, guilt feelings, anxiety) associated with schizophrenia. Risperidone also appears effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial response to treatment with this agent.
Product summary:
Package - Contents - Shelf Life: Blister pack, PVC/PE/PVdC and aluminium foil blister pack, packaged in a cardboard carton - 20 tablets - 36 months from date of manufacture stored at or below 25°C - Blister pack, PVC/PE/PVdC and aluminium foil blister pack, packaged in a cardboard carton - 60 tablets - 36 months from date of manufacture stored at or below 25°C
Authorization number:
TT50-9417b
Authorization date:
2013-10-23

Similar products

Search alerts related to this product

Share this information